The wrath of RAFs: Rogue behavior of B-RAF kinase inhibitors

Journal of Investigative Dermatology

Volumn 130, Issue 11, 2010, Pages 2669-2671

  Kaplan, Fred M ^a   Mastrangelo, Michael J ^a,b   Aplin, Andrew E ^a,b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [4 (1 HYDROXYIMINO 5 INDANYL) 3 (4 PYRIDINYL) 1H PYRAZOL 1 YL]ETHANOL; A RAF KINASE; B RAF KINASE INHIBITOR; C RAF KINASE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; PLX 4032; PLX 4720; PROTEIN SERINE THREONINE KINASE; RAF PROTEIN; RAS PROTEIN; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; CANCER GROWTH; CANCER INHIBITION; CELL MOTILITY; CELL MUTANT; CELL PROLIFERATION; DRUG MECHANISM; GENOTYPE; HOMEOSTASIS; HUMAN; IN VITRO STUDY; KERATOACANTHOMA; LETTER; MELANOMA; MELANOMA CELL; MUTATION; NONHUMAN; PATIENT SELECTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; XENOGRAFT;

EID: 77957964126     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2010.177     Document Type: Letter

References (12)

1. Davies H, Bignell GR, Cox C et al. (2002) Mutations of the BRAF gene in human cancer. Nature 417:949-54
2. Flaherty K, Puzanov I, Sosman J et al. (2009) Phase I study of PLX4032: proof of concept for V600E BRAF mutation as a therapeutic target in human cancer. J Clin Oncol 27: 15S (Abstract)
3. Halaban R, Zhang W, Bacchiocchi A et al. (2010) PLX4032, a selective BRAF V600E kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF WT melanoma cells. Pigment Cell Melanoma Res 23: 190-200
4. Hall-Jackson CA, Eyers PA, Cohen P et al. (1999) Paradoxical activation of Raf by a novel Raf inhibitor. Chem Biol 6:559-68
5. Hatzivassiliou G, Song K, Yen I et al. (2010) RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 464:431-5
6. Heidorn SJ, Milagre C, Whittaker S et al. (2010) Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 140:209-21
7. King AJ, Patrick DR, Batorsky RS et al. (2006) Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885. Cancer Res 66:11100-5
8. Michaloglou C, Vredeveld LC, Mooi WJ et al. (2008) BRAF(E600) in benign and malignant human tumours. Oncogene 27:877-95
9. Poulikakos PI, Zhang C, Bollag G et al. (2010) RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 464:427-30
10. Ritt DA, Monson DM, Specht SI et al. (2010) Impact of feedback phosphorylation and Raf heterodimerization on normal and mutant B-Raf signaling. Mol Cell Biol 30:806-19
11. Rushworth LK, Hindley AD, O'Neill E et al. (2006) Regulation and role of Raf-1/B-Raf hetero-dimerization. Mol Cell Biol 26:2262-72
12. Tsai J, Lee JT, Wang W et al. (2008) Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci USA 105:3041-6